Screening platform and biomarkers for prediction and prevention of diseases of unmet public health need
This EU funding program, "Screening platform and biomarkers for prediction and prevention of diseases of unmet public health need" (HORIZON-JU-IHI-2022-03-01), aims to combat the rising burden of disease in an aging European population. It specifically supports the development of innovative screening platforms and validated biomarkers to enable early identification of individuals at risk, leading to personalized and effective preventive interventions and improved public health outcomes.
Who is Funded
This section outlines the eligibility criteria for organizations and the strategic objectives of the funding program, focusing on advancing public health through early disease prediction and prevention. The program aims to support a broad range of entities, including research institutions, healthcare providers, and innovative businesses, in collaborative efforts across European and associated countries.
What is Funded
This section details the types of projects and activities eligible for funding, focusing on innovative health solutions from research to market introduction. It covers the thematic areas, acceptable costs, and the developmental stages targeted by the program.
Type and Scope of Funding
This section outlines the financial mechanisms and limits associated with the program, detailing the type of financial support provided and the expected funding amounts for successful projects.
Conditions and Requirements
This section covers the essential rules and criteria that applicants and beneficiaries must adhere to throughout the application and project implementation phases, encompassing administrative, collaborative, and ethical considerations.
Application Procedure
This section guides potential applicants through the procedural aspects of the funding program, from preparing and submitting proposals to understanding the evaluation and award processes.
Legal Basis
This section outlines the foundational legal documents governing the funding program, providing transparency on its authorization and operational framework.
Similar Programs
Funding Overview
Funding Status:
Closed
Maximum Amount:
15,000,000 €
Allocated Budget:
Between 10,000,000 € and 15,000,000 € per project.
Deadline:
15.03.2023
Award Channel:
Competitive Tender
Region:
Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, United Kingdom, Israel, Kenya, Turkey, Ukraine
Sectors:
Healthcare, Research and Development, Information and Communication Technology, Medical Technology, Pharmaceutical Industry, Green Technology
Beneficiaries:
Healthcare
Application Type:
Consortium Required
Funding Stages:
Applied Research, Experimental Development, Prototyping, Pilot Testing, Product Development, Market Introduction
Funding Provider
Program Level:
European Union
Funding Body:
European Commission, Innovative Health Initiative Joint Undertaking (IHI JU)
Managed By:
Innovative Health Initiative Joint Undertaking (IHI JU)
Additional Partners:
AITOWN S.R.L., Nuromedia GmbH, Rhino Health Ltd, BAR ILAN UNIVERSITY, MediWound Ltd., STRATHMORE UNIVERSITY, NATIONAL TECHNICAL UNIVERSITY OF UKRAINE IGOR SIKORSKY KYIV POLYTECHNIC INSTITUTE, UNIVERSIDAD DE LA IGLESIA DE DEUSTO ENTIDAD RELIGIOSA, MEDIREX GROUP ACADEMY n.o., Zeus Consulting IKE, TekPrivacy, Lda, Dorothy and Friends S.L., SYNYO GmbH, Metabio IKE, GRANTXPERT CONSULTING LIMITED, ARTIFICIAL INTELLIGENCE EXPERT SRL, Democritus University of Thrace (represented by Christos Kontogiorgis), Diabetis UAB, ALICE & BOB, IMC- INDUSTRIAL MANAGEMENT CONSULTING SLOVAKIA, S.R.O., MAGNES AG, FONDAZIONE EDO ED ELVO TEMPIA VALENTA - ONLUS, Department for Information Computer Systems and Control, West Ukrainian National University, RobotDreams GmbH, MINDS & SPARKS GMBH, Respibit LTD, Svezdrav, Innovative Technologies in Biological Systems, SQILLINE BUSINESS SOLUTIONS Ltd, FUNDACION PRIVADA HOSPITAL ASIL DEGRANOLLERS, Revio Pharmaceutical Consultants S.L., Michael BRACH, UNIVERSIDAD DE ALICANTE, INTERSPREAD GMBH, Higia Health Solutions SL, EDELWEISS CONNECT GMBH, GENERAL HOSPITAL OF PELLA, LASER CONSULT MUSZAKI-TUDOMANYOS ES GAZDASAGI TANACSADO KORLATOLT FELELOSSEGU TARSASAG, SYXIS VSI, Alexander NIKOLOV, GRANT GARANT SRO, EPSILON INTERNATIONAL LTD, ITEOS THERAPEUTICS, Ministry of Health, Antalya Provincial Directorate of Health, SENSICHIPS SRL, INSTITOUTO ANAPTIXIS EPICHEIRIMATIKOTITAS ASTIKI ETAIREIA, Fimo Health GmbH, Innoplexus, UDRUZENJE - KLASTER MEDICINSKOG I ZDRAVSTVENOG TURIZMA, IVANO-FRANKIVSK NATIONAL MEDICAL UNIVERSITY
Website: